Applied Therapeutics (APLT) Competitors $0.52 +0.03 (+5.56%) Closing price 04:00 PM EasternExtended Trading$0.52 0.00 (-0.21%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLT vs. DRUG, GLUE, SCPH, FDMT, CTNM, FHTX, TVRD, NMRA, CAPR, and MREOShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Bright Minds Biosciences (DRUG), Monte Rosa Therapeutics (GLUE), scPharmaceuticals (SCPH), 4D Molecular Therapeutics (FDMT), Contineum Therapeutics (CTNM), Foghorn Therapeutics (FHTX), Tvardi Therapeutics (TVRD), Neumora Therapeutics (NMRA), Capricor Therapeutics (CAPR), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. Its Competitors Bright Minds Biosciences Monte Rosa Therapeutics scPharmaceuticals 4D Molecular Therapeutics Contineum Therapeutics Foghorn Therapeutics Tvardi Therapeutics Neumora Therapeutics Capricor Therapeutics Mereo BioPharma Group Bright Minds Biosciences (NASDAQ:DRUG) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Does the media refer more to DRUG or APLT? In the previous week, Applied Therapeutics had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 3 mentions for Applied Therapeutics and 2 mentions for Bright Minds Biosciences. Applied Therapeutics' average media sentiment score of 1.33 beat Bright Minds Biosciences' score of 1.27 indicating that Applied Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Applied Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of DRUG or APLT? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer DRUG or APLT? Bright Minds Biosciences presently has a consensus price target of $83.25, suggesting a potential upside of 114.56%. Applied Therapeutics has a consensus price target of $6.10, suggesting a potential upside of 1,072.85%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation and earnings, DRUG or APLT? Bright Minds Biosciences has higher earnings, but lower revenue than Applied Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.93-41.72Applied Therapeutics$460K162.83-$105.62M-$0.45-1.16 Which has more volatility & risk, DRUG or APLT? Bright Minds Biosciences has a beta of -6.14, meaning that its share price is 714% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Is DRUG or APLT more profitable? Bright Minds Biosciences' return on equity of -20.96% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -20.96% -20.66% Applied Therapeutics N/A -354.24%-144.16% SummaryApplied Therapeutics beats Bright Minds Biosciences on 8 of the 15 factors compared between the two stocks. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.96M$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio-1.167.4762.2622.40Price / Sales162.83396.81537.34111.77Price / CashN/A43.5325.7028.92Price / Book4.338.1011.196.58Net Income-$105.62M-$53.35M$3.28B$265.84M7 Day Performance-2.51%-0.14%0.15%-0.07%1 Month Performance18.02%9.18%8.34%5.83%1 Year Performance-91.80%7.53%54.21%17.88% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics4.1274 of 5 stars$0.52+5.6%$6.10+1,072.9%-92.2%$70.96M$460K-1.1630Positive NewsGap UpDRUGBright Minds Biosciences2.7995 of 5 stars$43.14-0.5%$83.25+93.0%+3,567.9%$302.86MN/A-46.26N/ANews CoveragePositive NewsGLUEMonte Rosa Therapeutics2.8084 of 5 stars$4.80+2.8%$15.33+219.4%-22.2%$297.37M$75.62M13.3890News CoveragePositive NewsSCPHscPharmaceuticals3.839 of 5 stars$5.53+0.1%$12.00+117.2%+8.1%$294.47M$49.97M-3.0530Short Interest ↑FDMT4D Molecular Therapeutics2.3229 of 5 stars$6.26-3.1%$30.40+385.6%-59.0%$293.28M$40K-1.78120News CoverageAnalyst ForecastGap DownCTNMContineum Therapeutics2.6606 of 5 stars$10.36+3.4%$22.75+119.7%-46.4%$291.92MN/A-4.7331Short Interest ↑FHTXFoghorn Therapeutics2.7561 of 5 stars$5.15-4.8%$10.67+107.1%-38.9%$291.13M$22.60M-4.33120News CoveragePositive NewsTVRDTvardi TherapeuticsN/A$30.95+1.1%$64.25+107.6%N/A$290.31M$7.14M0.0080Positive NewsNMRANeumora Therapeutics3.2965 of 5 stars$1.79+1.4%$7.14+300.2%-85.0%$289.08MN/A-1.14108Positive NewsShort Interest ↓CAPRCapricor Therapeutics2.6402 of 5 stars$6.29+0.6%$22.56+258.6%+37.4%$288.93M$13.39M-3.85101MREOMereo BioPharma Group2.3621 of 5 stars$1.77+0.3%$7.40+319.3%-63.5%$280.64M$10M-25.2140 Related Companies and Tools Related Companies Bright Minds Biosciences Alternatives Monte Rosa Therapeutics Alternatives scPharmaceuticals Alternatives 4D Molecular Therapeutics Alternatives Contineum Therapeutics Alternatives Foghorn Therapeutics Alternatives Tvardi Therapeutics Alternatives Neumora Therapeutics Alternatives Capricor Therapeutics Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLT) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLT Stock Alerts